Evidence map›Paper›PMID 40592820›Full record

ArticleNature communications2025

Identification of immunogenic and cross-reactive chikungunya virus epitopes for CD4

Rimjhim Agarwal, Calvin Ha, Fernanda H Côrtes, Yeji Lee, Amparo Martínez-Pérez, Rosa Isela Gálvez, Izabella N Castillo, Elizabeth J Phillips, Simon A Mallal, Angel Balmaseda and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Comprehensive mapping of human CD4Cell reports. Medicine · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rimjhim Agarwal *Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6939-5077
Calvin Ha *Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.ORCID http://orcid.org/0009-0005-2028-886X
Fernanda H CôrtesCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.
Yeji LeeCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-2175-0049
Amparo Martínez-PérezCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-3898-5709
Rosa Isela GálvezCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9320-2570
Izabella N CastilloDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID http://orcid.org/0009-0003-2815-2807
Elizabeth J PhillipsInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia.
Simon A MallalInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia.
Angel BalmasedaSustainable Sciences Institute, Managua, Nicaragua.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-7238-4037
Claudia M Romero-VivasLaboratorio de Enfermedades Tropicales, Departamento de Medicina, Fundación Universidad del Norte, Barranquilla, Colombia.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-1736-1350
Andrew K FalconarLaboratorio de Enfermedades Tropicales, Departamento de Medicina, Fundación Universidad del Norte, Barranquilla, Colombia.ORCID http://orcid.org/0000-0002-2066-9487
Alba GrifoniCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-2209-5966
Alessandro SetteCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7013-2250
Daniela WeiskopfCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA. daniela@lji.org.ORCID http://orcid.org/0000-0003-2968-7371

Funding

Large Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination75N93019C00065 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI MITCHELL, MAYA · 2019 to 2023
$7.3M
THE IDENTIFICATION AND VALIDATION OF EPITOPES CONSERVED IN VIRAL PATHOGEN FAMILIES WITH PANDEMIC POTENTIAL75N93024C00056 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI FABRITZKY, BRANDON · 2024 to 2025
$2.1M
Multiplex serological assays to support arbovirus diagnosis, surveillance and vaccinesU24AI152170 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESILVA, ARAVINDA M., LAKSHMANANE, PREMKUMAR · 2020 to 2024
$2.1M
NIAID NIH HHS 75N93019C00065NIAID NIH HHS 75N93024C00056NIAID NIH HHS U24 AI152170
6 · The paper itself

Abstract

Chikungunya virus (CHIKV), a mosquito-borne alphavirus, causes acute febrile illness that can progress into chronic arthritis-like disease (CHIKVD) in humans. CD4

Indexed as

CD4-Positive T-LymphocytesChikungunya FeverChikungunya virusEpitopes, T-LymphocyteChronic DiseaseCross ReactionsFemaleHumansMaleEpitopes, T-Lymphocyte

Identifiers

PMID40592820
PMCPMC12218217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.